

B2 which comprises diluting the concentrate in an aqueous diluent prior to oral administration.

Please cancel claim 13.

Please retain claim 14.

Please amend claim 15 to read as follows:

15. (Amended) A method of treating or preventing diseases or conditions which are caused by disorders of the serotonergic system which comprises:

B3 a) diluting an essentially nonaqueous, liquid concentrate of sertraline hydrochloride of claim 1 in an aqueous diluent; and

b) orally administering the resulting aqueous solution to a patient in need thereof.

Please retain claim 16.

Please amend claim 17 to read as follows:

B4 17. (Amended) A method of treating or preventing diseases or conditions selected from the group consisting of depression, anorexia, chemical dependencies, anxiety-related disorders, premature ejaculation, cancer and post myocardial infarction, which comprises:

a) diluting an essentially nonaqueous, liquid concentrate of sertraline hydrochloride of claim 1 in an aqueous diluent; and

b) orally administering the resulting aqueous solution to a patient in need thereof.

Please retain claims 18 and 19.

REMARKS

Reconsideration of this application, as amended, is respectfully requested.

Claims 1-19 are pending in the present application. Of these claims, claims 12-19 has been withdrawn from consideration. Claims 1-11 have been rejected.

After the above amendments, claims 1, 7-12, and 14-19 remain in this application. For the Examiner's information, with the above amendments, claims 2-6 have been deleted; however, the subject matter of these claims, especially claim 6, has been incorporated into claim 1; and claims 7-11 have been retained. Claims 12, 15 and 17 have been amended; claim 13 has been deleted, and claims 14, 16, 18 and 19 have been retained. Also, a misspelling of "sertraline" in claims 15 and 17 has been corrected.